Anti-IgE for asthma in inner-city children

New England Journal of Medicine

Volumn 364, Issue 26, 2011, Pages 2556-2558

  Pavord, Ian D ^a   Bush, Andy ^b  

^a UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

^b ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN E; OMALIZUMAB;

ALLERGIC ASTHMA; CHILD; DISEASE CONTROL; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; EOSINOPHIL COUNT; HUMAN; LETTER; PHENOTYPE; PRIORITY JOURNAL; RESPIRATORY TRACT INFLAMMATION; SENSITIZATION; TREATMENT RESPONSE;

EID: 79959776423     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1104264     Document Type: Letter

References (4)

1. Busse WW, Morgan WJ, Gergen PJ, et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med 2011;364:1005-15.
2. Green RH, Brightling CE, McKenna S, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002;360:1715-21. (Pubitemid 35447900)
3. Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009;360:973-84. [Erratum, N Engl J Med 2011;364:588.]
4. Djukanović R, Wilson SJ, Kraft M, et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med 2004;170:583-93.